110,240 Shares in Health Catalyst, Inc. (NASDAQ:HCAT) Acquired by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC bought a new position in Health Catalyst, Inc. (NASDAQ:HCAT) in the third quarter, according to the company in its most recent disclosure with the SEC. The fund bought 110,240 shares of the company’s stock, valued at approximately $897,000. Janney Montgomery Scott LLC owned 0.18% of Health Catalyst at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Principal Financial Group Inc. increased its stake in Health Catalyst by 6.9% in the 2nd quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after buying an additional 1,907 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in Health Catalyst by 10.3% in the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock worth $148,000 after purchasing an additional 2,164 shares during the last quarter. Creative Planning grew its position in Health Catalyst by 13.2% in the third quarter. Creative Planning now owns 21,348 shares of the company’s stock worth $174,000 after acquiring an additional 2,486 shares in the last quarter. Quarry LP lifted its position in Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after buying an additional 2,610 shares during the last quarter. Finally, Probity Advisors Inc. grew its holdings in Health Catalyst by 13.3% during the 3rd quarter. Probity Advisors Inc. now owns 23,045 shares of the company’s stock valued at $188,000 after purchasing an additional 2,699 shares during the last quarter. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Price Performance

Shares of HCAT stock opened at $7.65 on Friday. The company has a market capitalization of $465.50 million, a PE ratio of -5.67 and a beta of 1.32. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The firm’s 50-day moving average is $8.16 and its two-hundred day moving average is $7.22. Health Catalyst, Inc. has a 12 month low of $5.42 and a 12 month high of $11.41.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. During the same period in the previous year, the firm earned ($0.22) EPS. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. Analysts predict that Health Catalyst, Inc. will post -0.35 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares in the company, valued at approximately $1,847,460.82. This represents a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Daniel Lesueur sold 8,137 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at approximately $1,062,018.64. This represents a 5.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,068 shares of company stock worth $257,555 in the last quarter. 2.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently commented on HCAT shares. Citigroup raised their price target on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Wednesday. Stephens boosted their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Thursday. JPMorgan Chase & Co. upped their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Piper Sandler lowered their price target on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 26th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Health Catalyst presently has an average rating of “Moderate Buy” and an average target price of $11.71.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.